Pfizer: Encephalitis, Tick-Borne trials

The registry lists 19 Encephalitis, Tick-Borne studies with Pfizer as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 2 5Phase 3 7Phase 4 7No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and OlderCompletedNCT04648241Phase 3Results posted
• Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)CompletedNCT00894686Phase 4Results posted
• Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in ChildrenCompletedNCT00840801Phase 3Results posted
• TBE Seropersistence up to 10 Years After First Booster in AdultsCompletedNCT01582698Phase 4
• TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223)CompletedNCT00503529Phase 4
• Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization ScheduleCompletedNCT00460486Phase 3
• Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in ChildrenCompletedNCT00163618
• Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)CompletedNCT00163540Phase 4
• TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)CompletedNCT00161967Phase 4
• Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 YearsCompletedNCT00161954Phase 4
• FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 YearsCompletedNCT00161889Phase 2
• FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 YearsCompletedNCT00161876Phase 3
• Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 YearsCompletedNCT00161863Phase 3
• FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 YearsCompletedNCT00161850Phase 2
• Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPURCompletedNCT00161824Phase 3
• Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.CompletedNCT00161798Phase 2
• Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 YearsCompletedNCT00161785Phase 4
• Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.CompletedNCT00161772Phase 2
• Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 YearsCompletedNCT00161746Phase 2/3